
The importance of re-evaluating the risk score in heart failure patients: An analysis from the Metabolic Exercise Cardiac Kidney Indexes (MECKI) score database

Beatrice Pezzuto, Massimo Piepoli, Arianna Galotta, Susanna Sciomer, Denise Zaffalon, Domenico Filomena, Carlo Vignati, Mauro Contini, Marina Alimento, Nikita Baracchini, Anna Apostolo, Pietro Palermo, Massimo Mapelli, Elisabetta Salvioni, Cosimo Carriere, Marco Merlo, Silvia Papa, Jeness Campodonico, Roberto Badagliacca, Gianfranco Sinagra, Piergiuseppe Agostoni



PII:	80167-5273(23)00110-9
DOI:	https://doi.org/10.1016/j.ijcard.2023.01.069
Reference:	IJCA 30850
To appear in:	International Journal of Cardiology
Received date:	17 January 2023
Accepted date:	23 January 2023

Please cite this article as: B. Pezzuto, M. Piepoli, A. Galotta, et al., The importance of reevaluating the risk score in heart failure patients: An analysis from the Metabolic Exercise Cardiac Kidney Indexes (MECKI) score database, *International Journal of Cardiology* (2023), https://doi.org/10.1016/j.ijcard.2023.01.069

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2023 Elsevier B.V. All rights reserved.

THE IMPORTANCE OF RE-EVALUATING THE RISK SCORE IN HEART FAILURE

PATIENTS: AN ANALYSIS FROM THE METABOLIC EXERCISE CARDIAC KIDNEY

INDEXES (MECKI) SCORE DATABASE.

Beatrice Pezzuto MD, PhD,^a Massimo Piepoli MD, PhD,^{bc} Arianna Galotta MSc,^a Susanna Sciomer MD, PhD,^d Denise Zaffalon MD,^e Domenico Filomena MD,^d Carlo Vignati MD,^a Mauro Contini MD,^a Marina Alimento MD,^a Nikita Baracchini MD,^e Anna Apostolo MD,^a Pietro Palermo MD,^a Massimo Mapelli MD, PhD,^{af} Elisabetta Salvioni PhD,^a Cosimo Carriere MD,^e Marco Merlo MD,^{eg} Silvia Papa MD,^d Jeness Campodonico MD,^a Roberto Badagliacca MD, PhD,^d Gianfranco Sinagra MD,^{eg} Piergiuseppe Agostoni MD, PhD.^{af}

^a Centro Cardiologico Monzino IRCCS, Milan, Italy - This author takes responseditive for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation

^b Department of Preventive Cardiology, Wroclaw Medical University, Vroclaw, Poland - This author takes responsibility for all aspects of the reliability and freedom from that of the data presented and their discussed interpretation

^c Department for Biomedical Sciences for Health, University of Min, n, It ily

^d Department of Cardiovascular and Respiratory Sciences, Somienza University of Rome, Italy - This author takes responsibility for all aspects of the reliability and freedon from bias of the data presented and their discussed interpretation

^e Cardiothoracovascular Department of Trieste, / zier la Sanitaria Universitaria Giuliano Isontina (ASUGI) and University of Trieste, Italy - This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation

^f Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy

^g Member of ERN GUARD-Heart

Address for correspondence:

Prof. Piergiuseppe Agostoni, MD, PhD

Centro Cardiologico Monzino, IRCCS

Department of Clinical Sciences and Community Health,

Cardiovascular Section, University of Milan

Via Parea, 4 - 20138 Milan, Italy

Phone 0039 02 58002772

Fax 0039 02 502008

E-mail piergiuseppe.agostoni@unimi.it;

piergiuseppe.agostoni@ccfm.it.

Conflict of interest to disclose: none

B. Pezzuto was partially funded by Fondazione Umberto Veronesi for this project

Abstract

Background. The role of risk scores in heart failure (HF) management has been highlighted by international guidelines. In contrast with HF, which is intrinsically a dynamic and unstable syndrome, all its prognostic studies have been based on a single evaluation. We investigated whether time-related changes of a well-recognized risk score, the MECKI score, added prognostic value. MECKI score is based on peak VO₂, VE/VCO₂ slope, Na⁺, LVEF, MDRD and Hb.

Methods. A multi-centre retrospective study was conducted involving 660 patients who performed MECKI re-evaluation at least 6 months apart. Based on the difference between II and I evaluation of MECKI values (MECKI II – MECKI I = Δ MECKI) the study population was divided in 2 groups: those presenting a score reduction (Δ MECKI <0, i.e. clinical improvement), vs. patients presenting an increase (Δ MECKI >0, clinical deterioration).

Results. The prognostic value of MECKI score is confirmed also when re-assessed during followup. The group with improved MECKI (366 patients) . Sowed a better prognosis compared to patients with worsened MECKI (294 patients) (p < 0.0001). At 1st evaluation, the two groups differentiated by LVEF, V_E/VCO₂ slope and blocd Na⁺ concentration, while at 2nd evaluation they differentiated in all 6 parameters considered in the score. The patients who improved MECKI score, improved in all components of the score but hemoglobin, while patients who worsened the score, worsened all parameters.

Conclusions. This study shows that re-assessment of MECKI score identifies HF subjects at higher risk and that score improvement or deterioration regards several MECKI score generating parameters confirming the holistic oackground of HF.

Key words: heart failure, prognosis, risk stratification, exercise capacity, hemoglobin, renal function

Introduction

Heart failure (HF) is currently one of the most relevant challenges in public health, occurring in 1-2% of developed countries adult population.¹ Despite significant treatment and management advances,¹ HF patients still have high mortality² and rehospitalization rates,³ thus a precise and individually tailored prognosis estimation is of main relevance to establish the appropriate treatment and patients' follow-up strategies. However, risk stratification in HF still remains a challenge mainly due to HF complex pathophysiology, presence of comorbidities, limited access to expensive and novel pharmacological and device therapies, and to sophisticated examinations such as cardiac magnetic resonance and genetic assessment.

Cardiopulmonary exercise test (CPET) is a well-recognized, easy to perform, cheap and accurate tool for risk stratification in HF. Among several CPET variables, peak VO_2 , $^{4,5}V_E/VCO_2$ slope, 10,6,7,8 and their combination 9,10 have been identified as strong and methods are dependent HF prognosis predictors.

Albeit several prognostic markers of death and/or HF hospitalization have been identified, it is currently recognized that the best strategy to p_1 vic HF prognosis or re-hospitalization is by multiparametric evaluation.¹ For this purpose, several multivariable prognostic risk scores have been developed.^{11,12,13,14,15,16}

Among the numerous HF prognostic store, the Metabolic Exercise Cardiac Kidney Indexes (MECKI) score¹⁷ is the only one in agrating CPET prognostic parameters of both cardiovascular and ventilatory response to effort while established clinical, laboratory and echocardiographic risk factors. MECKI score has been built and validated in a robust database derived from leading HF clinics in Italy. At present, NECKI score is indicated by ESC guidelines among useful HF prognostic scores¹ and, actually, a few reports showed its superiority compared to other scores such as Seattle HF model, HFSS, MAGICC,^{18,19} at least in an HF population in whom CPET can be performed.

The MECKI score is built considering the combination of the following parameters: peak oxygen uptake (VO₂) % of predicted value, V_E/VCO_2 slope, left ventricular ejection fraction (LVEF by cardiac ultrasounds Simpson method), hemoglobin (Hb), blood sodium value (Na⁺), and glomerular filtration rate as estimated by MDRD formula.¹⁷

The major limitation of all the observational prognostic studies in HF, including MECKI, is that they have been exclusively based on parameters evaluated once, i.e. at the beginning of the followup, both for incident and prevalent patients. The information of the role of a second evaluation during follow-up assessment is generally lacking with the exception of HFSS.²⁰ HF is a dynamic

condition where the clinical outcome can change dramatically over the course of the syndrome, related to cardiac and not cardiac factors. So repeated evaluations are of main relevance, allowing to update the risk profile and to monitor HF evolution, thereby improving the therapeutic strategy.

The purpose of this study was to investigate whether a second MECKI score evaluation and the analysis of MECKI score changes present an added prognostic value for HF morbidity and mortality prediction.

Study Design and Methods

The MECKI group registry

The MECKI group registry includes at present 7,700 consecu ive systolic HF patients, recruited and prospectively followed in 24 Italian HF centers since 1993, with mean follow-up > 3 years.²¹

Currently a similar registry with > 1,000 patients is only oing in other European countries and China.²²

MECKI score database inclusion/exclusion criteria have been previously reported in detail.¹⁷ In brief, inclusion criteria are: previous or present HF symptoms (NYHA classes I-III, stage C of ACC/AHA classification) and documentation of left ventricular systolic dysfunction (LVEF <40%), clinical stability with unchanged therapy for at least 3 months, ability to perform CPET, no major cardiovascular treatment or intervention scheduled. Exclusion criteria: history of pulmonary embolism, moderate-to-severe antic and mitral stenosis, pericardial disease, severe BPCO, exercise-induced angina and cignificant ECG alterations, presence of any clinical co-morbidity interfering with exercise performance.

Study protocol

We asked all MECKI score centers if they were able to retrospectively retrieve data of patients who performed a second MECKI score evaluation and three centers replied positively. Only patients who performed 2 MECKI score evaluations (MECKI I and II) at least 6-month apart were included. After the MECKI II estimation, the follow-up lasted up to 2 years to detect any morbidity and mortality event reported in the registry during this time period. All patients were regularly re-evaluated at the recruiting center. At the time of MECKI II, all patients included in the study were still able to perform CPET.

The study endpoint was the combination of death of any cause, hospitalization for HF, hospitalization for cardiovascular causes other than HF, left ventricular assist device (LVAD)

implantation and urgent heart transplantation. The first event occurred during follow-up was taken into consideration.

The investigation was approved by local Ethical Committee (notification n CCM 04-21 - RE 3635). All participants signed an informed consent. The study was conducted in compliance with the declaration of Helsinki.

Cardiopulmonary exercise test

All CPETs were performed using a cycle-ergometer, and a personalized ramp protocol was applied. The exercise was preceded by at least three minutes of rest gas exchange monitoring and by a short unloaded warm-up period. During the exercise test, 12-lead ECG, blood pressure, and heart rate were recorded, and oxygen saturation was monitored through or use oximeter. The participants either wore a nose clip and breathed through a mouthpiece, or use d a facemask connected to a mass flow-meter as they preferred. CPET was carried out and incorpreted using a standard technique.²³ The exercise protocol was set to achieve peak exercise is ~10 min.²⁴ In the absence of clinical events, CPET was interrupted when patients stated in a they had reached maximal effort. Breath-by-breath analysis of expiratory gases and vention was performed. Anaerobic threshold was measured by V-slope analysis of VO₂ and ¹⁷CO₂, and it was confirmed by ventilatory equivalents and end-tidal pressures of CO₂ and G₂ VO₂/work slope was measured throughout the entire exercise. V_E/VCO_2 slope was calculated is the slope of the linear relationship between V_E and VCO₂ from 1 min after the beginning of the loaded exercise and the end of the isocaphic buffering period. Peak exercise O₂ pulse was back vO₂/peak heart rate.

The MECKI score was calculated with the following algorithm: exp (k) / (1 + exp (k)) where k = 10.3464 - 0.0262 x Peak O_2 ($\sim pred$) +0.0472 x V_E/VCO₂ slope - 0.1086 x Hb (g/dL) - 0.0615 x Na⁺ (mmol / L) - 0.0699 x U/EF (\ll) - 0.0136 x MDRD (mL/min).¹⁷

Statistical analysis

Continuous variables were expressed as mean \pm SD, categorical variables as counts and proportions. The study population was divided in two groups based on the difference between II and I evaluation of MECKI score values (MECKI II – MECKI I = Δ MECKI). The paired t test was used to compare the means of the variables at baseline and at the second assessment of the MECKI score; the unpaired t test was used to compare the population groups divided by Δ MECKI score < or > 0 at baseline and at the second evaluation. The chi-square test was used for the analysis of categorical variables. Kaplan-Meier curves were used to assess event-free survival during follow-up. A p value <0.05 was considered statistically significant.

All statistical analyzes were performed using SAS statistical package v. 9.4 (SAS Institute Inc, Cary, NC).

Results

Study population

Six hundred and sixty patients were enrolled: the main clinical, laboratory, echocardiographic, ergospirometric and treatment characteristics at the time of MECKI I and MECKI II are shown in Table 1. Average time between MECKI I and MECKI II determin tion was 2.02 ± 1.18 years, while median value was 2.03 years (1.34-3). Most of patients were more (81%) and had an ischemic etiology of HF (47%); the mean age at MECKI I was 60.7 ± 12.2 years. Enrolled patients largely received the most up-to-date evidence-based medical ther by for HF at the time of both first and second evaluation.

Follow-up

The average follow-up after MECKI II was 1.5 ± 0.7 years, when 262 events were observed: 220 patients (84% of events, 33% of total study j opulation) were hospitalized for HF and 22 (8% of events) for cardiovascular causes other than HF; 6 patients (2% of events) died from cardiovascular causes, 13 (5% of events) died from 101-4 ardiovascular or unknown causes, 1 patient underwent LVAD implantation (0.4% of events). No patient underwent heart transplantation.

As above described, study population was divided in two groups based on the difference between MECKI II and MECKI I score values: 366 subjects presented a reduction of MECKI score (Δ MECKI < 0, follow-up after MECKI II = 1.6 ± 0.6 years), suggesting prognosis improvement, while 294 patients presented an increase, implying a worse prognosis (Δ MECKI < follow-up 1.3 ± 0.7 years).

The main clinical, laboratory, echocardiographic, ergospirometric and therapy-related characteristics of the two groups at the time of the baseline (MECKI I) and of the second evaluation (MECKI II) are shown in Table 2. In the group with Δ MECKI < 0, the MECKI score reduced from 7.73 ± 9.54 to 3.93 ± 5.75 (p > 0.0001), or 4.34 (2-9.15 IQR) to 2.01 (0.92-4.11), while in the group with Δ MECKI > 0 MECKI score increased from 5.64 ± 6.61 to 12.04 ± 12.77 (p > 0.0001) or from 3.48 (1.78-6.89) to 7.77 (3.19-15.44).

Table 3 highlights the differences between patients who improved vs. those who worsened MECKI score in the first and the second evaluation for the MECKI score and for each of the parameters

included in the score taken individually. At the first evaluation a small but statistically significant difference was observed for MECKI score, which was slightly lower in those who subsequently increased the score. Statistically significant differences were observed only for LVEF, V_E/VCO_2 slope and Na⁺, while at second evaluation significant differences were found for all the 6 parameters.

Without considering MECKI score parameters, there was no significant difference between improved and worsened patient at baseline evaluation concerning demographic, clinical and treatment characteristic, excluded MRA and ICD, more used in improved patients (See Table 5 in Supplemental Materials).

Analyzing the changes at follow-up compared to baseline of each single parameter of the MECKI score, we observed that the patients who improved the MECK^T score also showed a significant improvement in all components of the score except for Hb, while patients who worsened the score, showed a significant worsening of all parameters (Table 4).

Percent changes of the 6 MECKI score generating barameters are reported in Figure 1. In improved patients, the improvement of the parameters mainly regarded LVEF and peak VO₂ %, while patients who worsened the score presented changes $> 1'_2$ % for peak VO₂ % and V_E/VCO₂ slope.

Prognostic evaluation

Figure 2 shows the Kaplan-Meier CLIV'S of event-free survival for both study patients' groups in a 2-year follow-up: the subjects who have improved MECKI score during follow-up presented a better prognosis after MECK^T II evaluation compared to patients with worsened MECKI (p < 0.0001).

Figure 3 shows the event-free survival of study population divided into two group according the Δ (worsened or improved) for each of the parameters included in the MECKI score: at post MECKI II follow-up, patients who had improved LVEF, % VO₂ peak and V_E/VCO₂ slope showed a better prognosis than patients who had presented a worsening of the three parameters compared to MECKI I, while there was no statistically significant difference in event-free survival between patients who had improved or worsened MDRD, Hb and Na⁺.

In addition, we performed a 1:1 matching of our study population with a similar group from the MECKI registry. Patients from our study were matched by MECKI re-evaluation with patients from the registry by first MECKI evaluation. It follows from the results that there were no significant differences on the survival of the two populations considered (p=0.992). The latter information

confirms that on the average patients who underwent the second MECKI score evaluation represent a typical sample of MECKI score patients.

Discussion

The results of our study first confirm the usefulness of the MECKI score for the prognostic evaluation of patients with HFrEF, showing that also the second MECKI score determination has, *per se*, a strong prognostic power. But most importantly we showed that the time-dependent MECKI score changes bear a very important prognostic information. Specifically, when MECKI score indicates a prognostic improvement, i.e. its value falls, all parameters improved but Hb, while when MECKI score indicates a prognosis worsening, i.e. AECKI increases, all parameters increased. Of note, the MECKI score changes were driven by peak VO₂ % for both worsening and improvement, by LVEF for improvement and by V_E/VCO_2 slope for worsening. Finally, only changes of peak VO₂ %, V_E/VCO_2 slope and LVEF had an independent prognostic power.

The MECKI score is the only HF prognostic n del which integrates both peak VO₂ % and V_E/VCO_2 slope with established clinical, labor, tory and echocardiographic risk factors. The CPET derived MECKI score parameters are among those which most importantly drive time related prognostic changes, suggesting a key role of functional capacity, assessed by CPET, in HF prognosis.²⁵

A few other insights of our data s' ould be underlined. Firstly, we can observe that the patients who had worsened MECKI score compared to the patients who had improved it, have only slight differences in the parameters included in the score taken individually and it is not possible to preidentify patients who will worsen HF. Of note, all patients have moderate HF at MECKI I analysis. MECKI I score correctly characterized patients' prognosis for a given amount of time. Of note, patients with worsened MECKI even presented a slightly better score at baseline compared to patients who had subsequently improved the score. This means that patients starting from similar basal conditions can have a different disease trajectory which only the repetition of MECKI score can identify.

Secondly, we observed that the patients who improved the score, also improved in all single parameters, except Hb, while the worsened patients showed a significant worsening of all six score parameters. However, for the former group, the improvement was mainly driven by LVEF and peak VO₂ %, while for the latter the worsening was mainly attributable to peak VO₂ and V_E/VCO_2 slope (Figure 1). This finding above all confirms that HF as a multiorgan disease which must be assessed

as such, notwithstanding variables, related to functional/exercise capacity, play a predominant role in determining diseases evolution and prognosis.

Finally, by analyzing event-free survival in the study population divided into two groups according to improvement or worsening of each individual MECKI parameter, it can be observed that only peak VO₂ %, V_E/VCO₂ slope and LVEF show a value in prognostic stratification, while MDRD and Hb do not reach significance, and Na⁺ curves are almost superimposed for the entire duration of the follow-up. This confirms the importance of the multiparametric holistic approach of evaluation of HF, but also it confirms the prognostic power of CPET. It is interesting to note that the variables affecting the prognosis even if taken individually, are the same ones that drive the worsening or improvement of the score, and notably peak VO₂ significantly impacts both the improvement and the worsening of MECKI score. Accordingly, as regards peak VO₂ changes with time, our data are in line with those of Lund et al²⁰ who confirmed, albeit in a simpler population, the need to repeat the prognostic assessment in HF patients.

Study limitations

This study has some relevant limitations that need to be acknowledged.

First, it is a retrospective study, so definitive conclusions cannot be derived. Specifically, we do not know how often MECKI score should be repeated and if re-evaluation time varies with HF severity as it seems to be reasonable but not tester in the present study.

Secondly, the number of patient: is rather small when considering the prevalence of HF in the general population. Moreover, the population we studied is characterized by relatively low risk HFrEF patients mainly in NY.1A class II able to perform CPET, so the generalization of the reported findings to more server population or with different phenotypes such as preserved ejection fraction HF patients should not be done. Moreover, due to the present sample size, we did not attempt to group our population in more Δ MECKI classes albeit this would have been desirable. The present, therefore, must be considered as a first approach to the dynamic evaluation of HF prognosis through the MECKI score.

Conclusions

The results of our study confirm the value of the MECKI score in the prognostic assessment of patients with HFrEF and highlights the rationale and the usefulness of a re-evaluation of the score during the follow-up, which allow to identify those subjects at increased risk of morbidity and mortality. This could help physicians to improve tailored patients' follow-up strategies, risk stratification, and resources allocation.

putral provides the second

Figure 1. Percent changes of the 6 MECKI score generating parameters: left ventricular ejection fraction (LVEF), peak oxygen uptake (Peak VO₂) as a percent of predicted value, V_E/VCO_2 slope, glomerular filtration rate by MDRD formula (MDRD), hemoglobin (Hb), sodium concentration (Na⁺). In red patients who reduced MECKI score, Δ MECKI < 0, i.e. clinical improvement, in blue those who increased MECKI score, Δ MECKI > 0, i.e. clinical worsening.




Figure 2. Kaplan-Meier curves of event-free survival in 2-year follow-up for patients with improved (Δ MECKI < 0) and worsened (Δ MECKI > 0) MECKI score value at II evaluation compared to baseline.





Figure 3. Kaplan-Meier curves of event-free survival in 2-year follow-up for patients with improving and worsening of each MECKI score parameter taken individually at II evaluation compared to baseline. Hb: hemoglobin; MDRD: Modification of Diet in Renal Disease; MECKI: Metabolic Exercise Cardiac Kideney Indexes; Na⁺: serum sodium; Peak VO₂ %: percentage of predicted peak oxygen uptake; V_E/VCO_2 slope: ventilation to carbon dioxide production slope; Δ MECKI: MECKI II - MECKI I.



I MECKI evaluation	II MECKI evaluation (follow-	Р
(baseline)	up)	value

Age, years	60.7 ± 12.2	63.3 ± 12.1	< 0.0001
Gender, M/F (%)	534 (81) / 126 (19)		
BMI , Kg/m ²	26.8 ± 4.5	27.1 ± 4.5	NS
NYHA, class	2.1 ± 0.7	2.1 ± 0.7	NS
Ischemic etiology, n (%)	310 (47)		
MECKI score %	6.8 ± 8.4	7.5 ± 10.4	0.05
Δ MECKI score %		0.7 ± 9	
LVEF, %	33.5 ± 8.9	35.8 ± 10.4	< 0.0001
Peak VO ₂ , % predicted	61.5 ± 15.7	61.5 ± 15.7	NS
V _E /VCO ₂ , slope	31.7 ± 7	32.3 ± 7.6	0.05
MDRD , ml/min/1.73m ²	71.2 ± 22.8	70.2 ± 27.1	NS
Na ⁺ , mmol/L	139.4 ± 3	139.5 ± 2.8	NS
Hb, g/dL	13.9 ± 1.5	13.6 ± 1.6	< 0.0001
AF , n (%)	126 (19)	110 (17)	NS
LBBB , n (%)	179 (27)	166 (25)	NS
PM , n (%)	139 (21)	118 (18)	NS
ICD , n (%)	224 (34)	304 (46)	< 0.0001
CRT , n (%)	98 (15)	157 (24)	< 0.0001
Beta-blockers, n (%)	554 (84)	603 (91)	< 0.0001
ACE-I , n (%)	419 (63)	347 (53)	< 0.0001
ARB , n (%)	161 (24)	123 (19)	0.01
MRA , n (%)	367 (56)	389 (59)	NS
ARNI , n (%)	0	141 (21)	< 0.0001
Diuretics , n (%)	486 (74)	490 (74)	NS
Anti-platelet, n (%)	338 (.51)	341 (52)	NS
VKA , n (%)	205 (.71)	222 (34)	NS
NOAC , n (%)	2 ((3)	12 (2)	0.01
Amiodarone, n (%)	235 (35)	259 (39)	NS
Digoxin, n (%)	.7 (9)	41 (6)	NS
SGLT2i , n (%)	0	22 (3)	< 0.0001

Table 1. Clinical, laboratory. Chr/cardiographic, ergospirometric and treatment characteristics of

the global study population and II evaluation of MECKI score.

Data are expressed as mean \pm standard deviation, unless otherwise specified.

ACE-I: inhibitors of angiotensin-converting enzyme; AF: atrial fibrillation; ARB: angiotensin II receptor blockers; ARNI: angiotensin receptor neprilysin inhibitor; BMI: body mass index; CRT: cardiac resynchronization therapy; F: female; Hb: hemoglobin; ICD: intracardiac defibrillator; LBBB: left bundle branch block; LVEF: left ventricular ejection fraction; M: male; MDRD: Modification of Diet in Renal Disease; MECKI: Metabolic Exercise Cardiac Kidney Indexes; MRA: mineralocorticoid receptor antagonists; n: number; Na⁺: serum sodium; NYHA: New York Heart Association; NOAC: non-vitamin K antagonist oral anticoagulant; PM: pacemaker; SD: standard deviation; SGLT2i: sodium-glucose co-transporter 2 inhibitors; Peak VO₂ %: percentage of predicted peak oxygen uptake; V_E/VCO_2 slope: ventilation to carbon dioxide production slope; VKA: vitamin K antagonists; Δ : MECKI II - MECKI I.

Table 2. Clinical, laboratory, echocardiographic, ergospirometric and treatment characteristics of

the two groups of study patients (Δ MECKI < 0 and Δ MECKI > 0) at I and II evaluation of the score.

	ΔΝ	IECKI < 0	Δ MECKI > 0				
	MECKI I	MECKI II	P value	MECKI I	MECKI II	P value	
Age, years	60.5 ± 12.2	62.9 ± 11.8	< 0.0001	61 ± 12.1	63.7 ± 12.4	< 0.0001	
Gender, M/F (%)	299/68 (81/19)			234/59 (80/20)			
BMI , Kg/m ²	26.7 ± 4.2	27 ± 4.3	NS	26.9 ± 4.9	27.1 ± 4.7	NS	
NYHA, class	2.1 ± 0.7	2 ± 0.7	0.01	2.1 ± 0.7	2.2 ± 0.7	< 0.0001	
Ischemic etiology, n (%)	165 (50)			145 (55)			
MECKI score, %	7.7 ± 9.5	3.9 ± 5.7	< 0.0001	5.6 ± 6.6	12 ± 12.8	< 0.0001	
∆ MECKI score, %		-3.8 ± 5.9			-3.8 ± 5.9		
LVEF, %	32.6 ± 9	39 ± 9.8	< 0.0001	$34.^{<} \pm 8.8$	31.7 ± 9.6	< 0.0001	
Peak VO2, % predicted	60.9 ± 16	67.6 ± 18.9	< 0.0001	62 2 + 15.4	54.2 ± 15.7	< 0.0001	
V _E /VCO ₂ , slope	32.3 ± 7.6	30.3 ± 5.9	< 0.0001	. 1.0 = 6.2	34.9 ± 8.7	< 0.0001	
MDRD , ml/min/1.73m ²	71.4 ± 22.9	75.5 ± 28.6	0.0002	71 ± 22.3	63.6 ± 23.6	< 0.0001	
Na ⁺ , mmol/L	139.1 ± 3.1	139.8 ± 2.5	< 0.0001	$13 .8 \pm 2.9$	139.1 ± 3	0.0005	
Hb, g/dL	13.9 ± 1.5	13.9 ± 1.4	NS	13.9 ± 1.5	13.4 ± 1.7	< 0.0001	
AF , n (%)	79 (22)	60 (16)	NS	47 (16)	50 (17)	NS	
LBBB , n (%)	104 (30)	92 (25)	N.	75 (27)	74 (25)	NS	
PM , n (%)	66 (21)	52 (14)	0.01	73 (26)	66 (23)	NS	
ICD , n (%)	113 (31)	142 (39)	·`.05	111 (38)	162 (55)	< 0.0001	
CRT , n (%)	58 (16)	82 (22)	0.',5	40 (14)	75 (26)	0.0003	
Beta-blockers, n (%)	306 (83)	330 (90)	0.01	248 (85)	273 (93)	0.001	
ACE-I , n (%)	235 (69)	185 (50)	0.0005	184 (69)	162 (55)	NS	
ARB , n (%)	85 (23)	60 (ı 🤇	0.05	76 (26)	63 (2)	NS	
MRA , n (%)	220 (60)	219 (60)	NS	147 (50)	170 (58)	NS	
ARNI , n (%)	0	98 (?7)	< 0.0001	0	43 (15)	< 0.0001	
Diuretics , n (%)	261 (71)	20. (71)	NS	225 (77)	229 (78)	NS	
Anti-platelet, n (%)	178 (49)	186 (51)	NS	160 (55)	155 (53)	NS	
VKA , n (%)	119 (32)	21 (33)	NS	86 (29)	101 (34)	NS	
NOAC , n (%)	0	6 (2)	0.01	2 (100)	6 (2)	NS	
Amiodarone, n (%)	122 (33)	123 (34)	NS	122 (33)	136 (46)	0.036	
Digoxin, n (%)	35 (1^)	28 (8)	NS	35 (10)	13 (4)	NS	
SGLT2i , n (%)	<u> </u>	11 (3)	0.001	0	11 (4)	0.0008	

Data are expressed as mean \pm standard deviation, unless otherwise specified.

ACE-I: inhibitors of angiotensin- onverting enzyme; AF: atrial fibrillation; ARB: angiotensin II receptor blockers; ARNI: angiotensin receptor neprotysin inhibitor; BMI: body mass index; CRT: cardiac resynchronization therapy; F: female; Hb: hemoglobin; ICD: intracardiac defibrillator; LBBB: left bundle branch block; LVEF: left ventricular ejection fraction; M: male; MDRD: Modification of Diet in Renal Disease; MECKI: Metabolic Exercise Cardiac Kidney Indexes; MRA: mineralocorticoid receptor antagonists; n: number; Na⁺: serum sodium; NYHA: New York Heart Association; NOAC: non-vitamin K antagonist oral anticoagulant; PM: pacemaker; SD: standard deviation; SGLT2i: sodium-glucose co-transporter 2 inhibitors; Peak VO₂ %: percentage of predicted peak oxygen uptake; V_E/VCO_2 slope: ventilation to carbon dioxide production slope; VKA: vitamin K antagonists; Δ MECKI: MECKI II -MECKI I.

	l	MECKI I		MECKI II			
	Improved	Worsened	P value	Improved	Worsened	P value	
	Δ MECKI < 0	Δ MECKI > 0		Δ MECKI < 0	Δ MECKI > 0		
Patients, n				366	294		
MECKI score, %	7.73±9.54	5.64 ± 6.61		3.93 ± 5.75	$12.04{\pm}12.77$		
MECKI score, % (median value)	4.34 (2-9.15)	3.48 (1.78-6.89)	0.0073	2.01 (0.92-4.11)	7.77 (3.19-15.44)	<.0001	
LVEF , %	32.6±9	34.6±8.8	0.0049	39±9.8	31.7±9.6	<.0001	
Peak VO ₂ , % predicted	60.9±16	62.2±15.4	NS	67.6±18.9	54.2±15.7	<.0001	
V _E /VCO ₂ , slope	32.3±7.6	31±6.2	0.0186	. े 3±5.9	34.8±8.7	<.0001	
MDRD , ml/min/1.73m ²	71.4±22.9	70.8±22.3	NS	75.5±28.6	63.6±23.6	<.0001	
Na ⁺ , mmol/L	139.1±3.1	139.8±2.9	0.0025	121/.8±2.5	139.1±3	0.0007	
Hb, g/dL	13.9±1.5	13.9±1.5	NS	13.9±1.4	13.4±1.7	<.0001	

Table 3. Comparison between improved and worsened patients at I e II MECKI evaluation for global score and for included parameters taken individually.

Data are expressed as mean \pm standard deviation, unless otherwise spec ified.

Hb: hemoglobin; LVEF: left ventricular ejection fraction; n: num' er; N DRD: Modification of Diet in Renal Disease; MECKI: Metabolic Exercise Cardiac Kidney Indexes; Na⁺: se⁻un. sodium; NS: non significant; Peak VO₂ %: percentage of predicted peak oxygen uptake; V_E/VCO_2 slr_P. ventilation to carbon dioxide production slope; Δ MECKI: MECKI II - MECKI I. **Table 4.** Changes of 6 MECKI parameters at II from I evaluation for improved and worsened patients.

	Improved patients (A MECKI < 0)			Worsened patients (A MECKI > 0)				
	MECKI I	MECKI II	Δ	Р	MECKI I	II MECKI	Δ	Р
LVEF , %	32.6 ± 9	39 ± 9.8	6.43±8.28	<.0001	34.6 ± 8.8	31.7 ± 9.6	-2.86±6.75	<.0001
Peak VO2, % predicted	60.9 ± 16	67.6 ± 18.9	6.75±13.21	<.0001	62.2 ± 15.4	54.2 ± 15.7	-7.98±13.51	<.0001
V _E /VCO ₂ , slope	32.3 ± 7.6	30.3 ± 5.9	-1.98±6.12	<.0001	31 ± 6.2	34.9 ± 8.7	3.86±6.49	<.0001
MDRD, ml/min/1.73m ²	71.4 ± 22.9	75.5 ± 28.6	4.1±20.8	0002	71 ± 22.3	63.6 ± 23.6	-7.25±19.37	<.0001
Na ⁺ , mmol/L	139.1 ± 3.1	139.8 ± 2.5	0.75±3.39	<.0001	139.8 ± 2.9	139.1 ± 3	-0.69±3.47	0.0007
Hb, g/dL	13.9 ± 1.5	13.9 ± 1.4	0.01±1.29	NS	13.9 ± 1.5	13.4 ± 1.7	-0.56±1.47	<.0001

Data are expressed as mean \pm standard deviation.

Hb: hemoglobin; LVEF: left ventricular ejection fraction; MDRD: $Mod^{(c)}$ and d Diet in Renal Disease; MECKI: Metabolic Exercise Cardiac Kideney Indexes; Na⁺: serum sodium; NS: non significant; Peak VO₂ %: percentage of predicted peak oxygen uptake; V_E/VCO₂ slope: ventilation to carbon c'oxide production slope; Δ MECKI: MECKI II - MECKI I.

References

THE IMPORTANCE OF RE-EVALUATING THE RISK SCORE IN HEART FAILURE PATIENTS: AN ANALYSIS FROM THE METABOLIC EXERCISE CARDIAC KIDNEY INDEXES (MECKI) SCORE DATABASE.

Highlights

- International guidelines have highlighted the role of risk scores in heart failure (HF).
- MECKI score is one of the prognostic models recommended by the European HF guidelines.
- Although HF is a dynamic syndrome, prognostic studies have then based on a single evaluation.
- The prognostic power of MECKI score is confirmed at a II evaluation during follow up.
- Re-evaluation of MECKI score during follow up identifes nr subjects at higher risk.

¹ McDonagh TA, Metra M, Adamo M, et al. 2021 F'₅C Guidelines for the diagnosis and treatment of acute and chronic heart failure: Develope , by the The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the HF Association (HFA) of the ESC. Eur Heart J 2021;42(36):3599-3726.

² Mamas MA, Sperrin M, Watson M[^] et al. Do patients have worse outcomes in heart failure than in cancer? A primary care-based c hort study with10-year follow-up in Scotland. Eur J Heart Fail 2017;19(9):1095-1104.

³ Lawson CA, Zaccardi F, Squire et al. 20-year trends in cause-specific heart failure outcomes by sex, socioeconomic status, and place of diagnosis: a population-based study. Lancet Public Health 2019;4(8):e406-e420.

⁴ O'Neill JO, Young JB, Pothier CE, Lauer MS. Peak oxygen consumption as a predictor of death in patients with heart failure receiving beta-blockers. Circulation 2005;111(18):2313-8.

⁵ Opasich C, Pinna GD, Bobbio M, et al. Peak exercise oxygen consumption in chronic heart failure: toward efficient use in the individual patient. J Am Coll Cardiol 1998;31(4):766-75.

⁶ Kleber FX, Vietzke G, Wernecke KD, et al. Impairment of ventilatory efficiency in heart failure: prognostic impact. Circulation 2000;101(24):2803-9.

⁷ Ponikowski P, Francis DP, Piepoli MF, et al. Enhanced ventilatory response to exercise in patients with chronic heart failure and preserved exercise tolerance: marker of abnormal cardiorespiratory reflex control and predictor of poor prognosis. Circulation 2001;103(7):967-72.

⁸ Arena R, Myers J, Abella J, et al. Development of a ventilatory classification system in patients with heart failure. Circulation 2007;115(18):2410-7.

 9 Francis DP, Shamim W, Davies LC, et al. Cardiopulmonary exercise testing for prognosis in chronic heart failure: continuous and independent prognostic value from V_E/VCO₂ slope and peak VO₂. Eur Heart J 2000;21(2):154-61.

¹⁰ Corrà U, Mezzani A, Bosimini E, Scapellato F, Imparato A, Giannuzzi P. Ventilatory response to exercise improves risk stratification in pacents with chronic heart failure and intermediate functional capacity. Am Heart J 2002;1/2(3).418-26.

¹¹ Pocock SJ, Ariti CA, McMurray J.V, et al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J 2013;34(19):1404-1413.

¹² Rahimi K, Bennett D, Co.vrad N, et al. Risk prediction in patients with heart failure. JACC Heart Fail 2014;2(5):440-446.

¹³ Ouwerkerk W, Voors AA, Zwinderman AH. Factors influencing the predictive power of models for predicting mortality and/or heart-failure hospitalization in patients with heart failure. JACC Heart Fail 2014;2(5):429-436.

¹⁴ Lupón J, de Antonio M, Vila J, et al. Development of a novel heart failure risk tool: the Barcelona bio-HF risk calculator (BCN bio-HF calculator). PLoS One 2014;9(1):e85466.

¹⁵ Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006;113(11):1424-1433.

¹⁶ Mozaffarian D, Anker SD, Anand I, et al. Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation 2007;116(4):392-398.

¹⁷ Agostoni P, Corrà U, Cattadori G, et al; MECKI Score Research Group. Metabolic exercise test data combined with cardiac and kidney indexes, the MECKI score: A multiparametric approach to HF prognosis. Int J of Cardiology 2013;167(6):2710-2718.

¹⁸ Agostoni P, Paolillo S, Mapelli M, et al Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a long-term comparison. Eur J Hea ⁺ Fail 2018;20(4):700-710.

¹⁹ Freitas P, Aguiar C, Ferreira A, Tralhão A, Ventosa A, Mende M. Comparative analysis of four scores to stratify patients with heart failure and reduce jection fraction. Am J Cardiol 2017;120(3):443-449.

²⁰ Lund LH, Aaronson KD, Mancini DM. Validation of peak exercise oxygen consumption and the Heart Failure Survival Score for serial risk scratification in advanced heart failure. Am J Cardiol 2005;95(6):734-41.

²¹ Magrì D, Piepoli M, Gallo G, et al. O'd and new equations for maximal heart rate prediction in patients with heart failure and reduced ejection fraction on beta-blockers treatment. results from the mecki score dataset. Eur J Prev Car Jiol 2022;29(12):1680-1688.

²² Salvioni E, Bonomi A, K, F, et al. The MECKI score initiative: Development and state of the art. Eur J Prev Cardiol. 2020;27(2_suppl):5-11.

²³ Agostoni P, Dumitrescu D. How to perform and report a cardiopulmonary exercise test in patients with chronic heart failure. Int J Cardiol 2019;288:107-113.

²⁴ Agostoni P, Bianchi M, Moraschi A, et al. Work-rate affects cardiopulmonary exercise test results in heart failure. Eur J Heart Fail 2005;7(4):498-504.

²⁵ Laoutaris ID, Piotrowicz E, Kallistratos MS, et al. Combined aerobic/resistance/inspiratory muscle training as the 'optimum' exercise programme for patients with chronic heart failure: ARISTOS-HF randomized clinical trial. Eur J Prev Cardiol 2021;28(15):1626-1635.

Sont of the second seco